Drugs / AZD8309
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT00860821 Comparator | Mar → Oct 2009 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00860821 ↗ |
| Route | Oral | “AZD8309 (300 mg) or placebo was dosed twice daily orally for 3 days prior to challenge with inhaled LPS and induced sputum was collected 6 h later.” PMID 24341382 ↗ Dec 2013 |
| Target | CXCR2 | “We investigated the effect of AZD8309, a CXCR2 antagonist, compared with placebo on LPS-induced inflammation measured in sputum of healthy volunteers.” PMID 24341382 ↗ Dec 2013 |